Executives at three vaccine manufacturers – GSK, Moderna, and CSL Seqirus told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.
Posts
GSK’s chief scientist says an overhaul of the drugmaker’s R&D unit has begun delivering results and pledged a tighter focus than his predecessor on infectious disease and HIV.
If approved, the combo vaccine could simplify the immunization schedule in the United States and likely expand GSK’s already dominant market share there for vaccines used to prevent illnesses caused by meningococcal bacteria.
GSK expects to launch its respiratory syncytial virus (RSV) vaccine in the U.S. this year without supply constraints and sees China as a major future market for the shot, a senior executive told Reuters.
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) agreed that GSK’s respiratory syncytial virus vaccine candidate is safe and effective in older adults.
Haleon, carved out of British drugmaker last July in the biggest listing in Europe for more than a decade, is the world’s biggest standalone consumer health business selling non-prescription drugs, vitamins and oral care products.
Tuesday, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) deemed there were enough data to support Pfizer’s respiratory syncytial virus (RSV) vaccine RSVpreF in adults aged 60 and older.
The frontrunners in a crowded race to develop the first respiratory syncytial virus vaccine – Pfizer Inc and GSK – will face scrutiny from a panel of experts to the U.S. Food and Drug Administration this week.
British drugmaker GSK’s HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.
Pfizer notched another score in the race for an RSV vaccine Tuesday, as it announced the FDA has accepted the Biologics License Application for its maternal RSV vaccine and granted the candidate priority review.
